25th May 2022 | Pharma Updates
Medley Pharma expected to be sold for Rs 5,000 crore
Medley Pharma, a privately held company based in Mumbai, is for sale. Cipla, Dr Reddy’s, KKR-backed JB Chemicals, and Torrent, as well as marquee private equity investors Advent, Carlyle, and Blackstone, are all considered potential buyers for the Rs 1,000-crore business.
New regulations for doctors' professional conduct being proposed
The National Medical Commission has proposed that doctors refrain from providing consultations and sharing prescriptions on social media, as well as refrain from purchasing “likes” or “followers” or paying money to keep their names at the top of search algorithms.
Alembic Pharma received approval from USFDA to market Pirfenidone tablets
US Food and Drug Administration has given final approval to Alembic Pharmaceuticals’ abbreviated new drug application (ANDA) for Pirfenidone Tablets, 267 mg and 801 mg.
Biohaven's neurological disease drug fails late-stage testing
Biohaven Pharmaceutical announced that its experimental drug for patients with spinocerebellar ataxia, a genetic disease affecting the nervous system, did not meet the primary goal of a late-stage study.
Halozyme completed its acquisition of Antares Pharma
Halozyme completed its Antares acquisition by merging a wholly owned subsidiary of Halozyme, in accordance with Section 251(h) of the General Corporation Law of the State of Delaware.
Piramal Pharma Solutions expands oral solid dose capabilities at Pithampur site
Piramal Pharma Limited’s Pharma Solutions business, a leading Contract Development and Manufacturing Organization, announced that the startup of a new production block at the company’s drug product site in Pithampur, Madhya Pradesh, India.
FDA lifted clinical hold on Ocugen's COVID vaccine trial
Ocugen IncUS announced that the US Food and Drug Administration had lifted the clinical hold on a mid-to-late stage trial of the COVID19 vaccine being developed by its Indian partner Bharat Biotech.